Corrigendum: Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer.

This Article contains errors in Table 1 and Table 4. The correct Table 1 and Table 4 appear below as Table 1 and Table 2 respectively.

Table 1

Clinicopathological characteristics of PTC patients in the FUSCC and TCGA cohorts.

Variables	TCGA (N = 471)		FUSCC (N = 185)		P value
	N	%	N	%
Age (years)					0.099
<45	217	46.1	99	53.5
≥45	254	53.9	86	46.5
Gender					0.374
Male	126	26.8	43	23.2
Female	345	73.2	142	76.8
Multifocality					<0.001
Unifocal	250	54.2	135	73.0
Multifocal	211	45.8	50	27.0
Histological type					<0.001
Classical PTC	329	70.9	183	98.9
Follicular PTC	99	21.3	2	1.1
Tall-cell PTC	36	7.8	0	0
Coexistent HT					0.004
Yes	66	14.0	44	23.8
No	405	86.0	141	76.2
ETE					<0.001
No	313	66.5	168	90.8
Yes	144	30.6	17	9.2
NA	14	3.0	0	0
T Stage					<0.001
T1-T2	282	59.9	166	89.7
T3-T4	188	39.9	19	10.3
NA	1	0.2	0	0
LNM					<0.001
N0	215	45.6	85	45.9
N1	210	44.6	100	54.1
NA	46	9.8	0	0
M					<0.001
M0	263	55.8	185	100
M1	8	1.7	0	0
NA	200	42.5	0	0
TNM Stage					<0.001
I-II	312	66.2	152	82.1
III-IV	157	33.3	33	17.9
NA	2	0.4	0	0
BRAFV600E					<0.001
Mutation	222	47.1	103	55.7
Wild-type	177	37.6	79	42.7
NA	72	15.3	3	1.6

Notes: Italic and bold type indicates statistical significance. Abbreviations: PTC, papillary thyroid cancer; FUSCC, Fudan University Shanghai Cancer Center; TCGA, The Cancer Genomics Atlas; HT, Hashimoto’s thyroiditis; ETE, extrathyroidal extension; LNM, lymph node metastasis; M, metastasis; TNM, tumor-node-metastasis.

Table 2

Cox proportional hazards analysis of factors associated with RFS for PTC patients in TCGA cohort.

Variables	Univariate analysis			Multivariate analysis
	P valuea	HR	95.0% CI for HR	P valuea	HR	95.0% CI for HR
Ageb	0.195	1.016	0.992–1.040	0.977	1.000	0.968–1.034
Genderb
Male		1			1
Female	0.009	0.350	0.159–0.769	0.021	0.386	0.172–0.868
Multifocality
Unifocal		1
Multifocal	0.106	1.933	0.868–4.300
Histological subtypesb
Classical PTC		1			1
Follicular PTC	0.913	0.941	0.318–2.786	0.871	1.095	0.367–3.269
Tall-cell PTC	0.202	2.229	0.650–7.641	0.886	1.098	0.306–3.949
Coexistent HT
No		1
Yes	0.740	1.729	0.648–4.616
ETE
No		1
Yes	0.182	1.712	0.777–3.773
T stageb
T1-T2		1			1
T3-T4	0.047	2.294	1.010–5.211	0.508	1.401	0.516–3.806
LNM
No		1
Yes	0.111	2.077	0.846–5.100
TNM stageb
Stage I-II		1			1
Stage III-IV	0.052	2.176	0.992–4.773	0.664	1.326	0.371–4.738
BRAFV600E
Wild-type		1
Mutation	0.365	1.557	0.597–4.057
LINC00271b
≥cutoff		1			1
<cutoffc	0.009	3.688	1.384–9.829	0.025	3.182	1.160–8.726

Notes: aItalic and bold type indicates statistical significance; badjusted by age, gender, histological subtypes, T stage, TNM stage and LINC00271 in multivariate analysis; c, LINC00271 expression level less than the best cutoff value for prediction of recurrence; Abbreviations: PTC, papillary thyroid cancer; TCGA, The Cancer Genomics Atlas; OR, odds ratio; CI, confidence interval; HT, Hashimoto’s thyroiditis; ETE, extrathyroidal extension; LNM, lymph node metastasis; TNM, tumor-node-metastasis.